However, anti-tumor effects of LPS/TLR4 agonists are consistently reported in fully immune competent animals, the majority showing greater survival time, curative remission in a significant % of test groups similar to Coley’s toxin, reduction of adverse effects of chemotherapy and radiation, including resistance (130–133, 176–178), and effects augmented when combined with anti-tumor cytokines (e.g. G-CSF) (134). This evidence concerns the gene CSF3 and neoplasm.